T Therapeutics
Cambridge, GB · 5 known investors
T-Therapeutics develops bispecific TCR-CD3 T cell engagers built on its OpTiMus TCR discovery platform to target previously undruggable intracellular targets. It creates first-in-class therapies for patients with cancer and autoimmune diseases, with lead programs in oncology (solid tumors) and immunology.
BiotechDeep TechHealthtech
Investors · 5
Frequently asked questions
- What does T Therapeutics do?
- T-Therapeutics develops bispecific TCR-CD3 T cell engagers built on its OpTiMus TCR discovery platform to target previously undruggable intracellular targets. It creates first-in-class therapies for patients with cancer and autoimmune diseases, with lead programs in oncology (solid tumors) and immunology.
- Who are T Therapeutics's investors?
- T Therapeutics's investors include F-Prime Capital, Sanofi Ventures, Sofinnova Partners, Cambridge Innovation Capital, Digitalis Ventures.
- Where is T Therapeutics headquartered?
- T Therapeutics is headquartered in Cambridge, GB.